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India is committed to eliminate filariasis by 2015. To
achieve this goal annual mass drug administration
(MDA) of diethylcarbamazine (DEC) was launched
in 2004 by the Government of India1,2. According
to the guidelines, DEC should be administered un-
der supervision to all people excluding children <2
yr, pregnant women and severely ill persons (non-
eligible).  The recommended DEC dosage is one tab-
let (100 mg) to children of age 2–5 yr, two tablets
for 6–14 yr age group, three tablets for those > 15 yr
of age3. In Puducherry, MDA programme is success-
ful with 97% coverage rate and the microfilaria rate
decreased from 0.42% in 2004 to 0.05% in 20084.
However, further success depends on effective com-
munication strategy of the drug distributors to im-
prove compliance2. DEC is distributed by filaria pre-
vention assistants (FPA)–health workers, Anganwadi
workers and volunteers such as women self help
group members and Panchayat members. FPA are
expected to ensure optimum consumption by: (i) enu-
merating family members; (ii) preparing them for
MDA; (iii) administering DEC; (iv) ensuring super-
vised consumption; (v) referring subjects with side
reactions to Primary Health Centre; and (vi) submit-
ting report. We evaluated the adherence of filaria pre-
vention assistants to the national guidelines. This in-
formation will be useful for future planning and
training of FPA.
This cross-sectional study was undertaken in two
feasibly selected villages (Koonichampattu and
Vadanoor) of rural Puducherry, having a total popu-
lation of 5172. Considering 6% difference in com-
pliance rate5 the calculated sample size was 1444
with α error of 5% and relative precision of 5%6. As
this constituted to around 30% of the study popula-
tion, every third house was systematically selected
for the study. After obtaining oral informed consent,
trained medical undergraduates, interviewed either
the head of the family or his wife within one month
of administration of 2008 MDA (November) using a
pre-designed and pre-tested structured questionnaire.
He/She was taken as the proxy respondent for all the
family members. The interviewers assessed the eligi-
bility of the household members for receiving DEC.
Information about the drug distributor, number of
DEC tablets given, that consumed and time of con-
sumption was collected. Five percent questionnaires
were rechecked for completeness by the faculty of
Department of Community Medicine. By following
this procedure the team collected data from 289
houses with 1282 individuals and 73 houses were
found locked. Data were analyzed using SPSS Ver-
sion 13. Nandha et al2 observed that people trust
anganwadi worker as a government representative
and complied with MDA. Hence, staff of health cen-
tres and anganwadi workers were clubbed together
as one group. Rates were calculated separately for
the staff of health centre/anganwadi and volunteers.
Chi-square test and Fisher’s exact tests of signifi-
cance were utilized. Odds ratio (OR) and the 95%
confidence intervals (95% CI) were also calculated.
Of the 1282 individuals surveyed, 661 (51.6%) were
females and 936 (73%) were literates. As per the
guidelines, 1231 (96%) were eligible to receive DEC.
This survey revealed that 938 (76.2%) of the 1231
eligible persons received DEC during the MDA (cov-
erage rate) and 88.7% of them consumed it (compli-
ance rate). The ‘Effective coverage rate’ which is a J  VECTOR  BORNE  DIS  47, JUNE 2010 114
product of coverage rate and compliance rate, was
67.6% (95% CI: 65–70.2). Sixty-seven houses with
221 persons were missed by the drug distributors in
the MDA programme and 13 members could not
recall the details about the drug distributors. Exclud-
ing these persons, finally data pertaining to 997 sub-
jects (958 eligible persons + 39 non-eligible persons)
were analyzed. Majority (78.3%) of the 958 eligible
persons received DEC from staff of health centre/
anganwadi, while the rest 21.7% received it from
other volunteers.
Both the groups of drug distributors made errors in
assessing for eligibility to receive DEC, where some
eligible subjects were misclassified as non-eligible and
vice-versa. Misclassification error did not vary sig-
nificantly between the drug distributors (p >0.05,
Table 1).  Of the eligible subjects who received DEC,
751 (86.7%) received the recommended dose of
DEC. Age based sub-analysis found that under-dos-
ing to children were nine times (OR= 9, 95% CI:
2.5–32.8, p <0.001) more by volunteers when com-
pared with staff of health centre/anganwadi whereas
in adults, dosing was similar by both the drug dis-
tributors. Compliance to MDA was 5.6 times (OR =
5.6; 95% CI: 3.4–9.1) better when distributed by staff
of health centre/anganwadi as compared to volun-
teers. Supervised DEC consumption was better
(OR=3; 95% CI: 1.2–7.2) with volunteers (Table 1).
In this study the coverage, compliance and effective
coverage rates were 76.2, 88.7 and 67.6% respec-
tively. A similar coverage and compliance rates were
observed in Karnataka7. In Orissa and Madhya
Pradesh consumption rates were lower8,9. In
Karnataka, 16.4% of the persons who failed to con-
sume the distributed drugs were children as their
parents feared to give the drugs to their children10.
Misclassification and distribution of incorrect dos-
age of DEC especially to children would affect the
compliance and reputation of the programme. Hence,
it warrants re-training for the drug distributors with
special emphasis on volunteers and the dosage sched-
ule for children, even though it was the fourth round
of MDA. Poor compliance among persons who re-
ceived DEC from volunteers, is of concern as good
Table 1. Comparison of adherence to guidelines and compliance during mass drug administration
between the staff of health centre/anganwadi and volunteers
Characteristics Total no.  No. of Health centres/ No. of volunteers p-value
of persons Anganwadis (%)  (%)
Distribution of DEC to the persons based on the eligibility criteria for MDA, n= 997*
Eligible persons given DEC 925 726 (93) 199 (92.1) 0.255
Eligible persons not given DEC 33   27 (3.5)     6 (2.7)
Non-eligible persons not given DEC 36   27 (3.5)    9 (4.2)
Non-eligible persons given DEC 3    1 (0.1)    2 (0.9)
Dose of DEC received by the eligible persons, n = (925–59) = 866**
Recommended dose 751 604 (87.4) 147 (84) 0.063
Higher dose 59   49 (7.1) 10 (5.7)
Lower dose 56   38 (5.5) 18 (10.3)
Compliance of eligible persons who received the recommended dose, n=751
Consumed DEC 671 565 (93.5) 106 (72.1) <0.001
Not consumed DEC 80  39 (6.5)  41 (27.9)
Supervised consumption among the eligible persons who consumed the recommended dose of DEC, n=671
Supervised 23   15 (2.7)   8 (7.5) 0.019
Non-supervised 648 550 (97.3) 98 (92.5)
*Excludes individuals in missed house (221) and who did not know the details of the DD (13); **Excludes persons who could not recall the
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compliance is crucial to consolidate the gains of the
earlier round of MDA to eliminate filariasis8,11. In
Tamil Nadu, it was found that lack of confidence on
the drug distributor is one of the reasons limiting
compliance11. Poor compliance among persons who
received DEC from volunteers may be due to the
volunteer’s poor communication skills. People may
also doubt the volunteer’s ability to assess the eligi-
bility for DEC and to dispense correct dose of DEC.
This is particularly true as it was found that motiva-
tion of drug distributors was one of the common rea-
son for better compliance. However, in places where
youth clubs and women groups were actively in-
volved, distribution and consumption rates were
higher12. These findings highlight the need for ap-
preciable enhancing the people’s confidence on vol-
unteers by: (i) incorporating the message ‘volunteers
are adequately trained and closely supervised by the
health centre staff’; (ii) better supervision of volun-
teers; and (iii) re-training.  Despite certain drawbacks
in involving volunteers, they were successful in mo-
tivating supervised consumption of DEC.
The findings of the present study should be seen in
the light of the limitation that the sample was from a
limited geographical area and the FPA were not in-
terviewed. Without the involvement of volunteers
MDA programme may suffer hence, measures tai-
lored to the local environment guided by operational
research is needed.
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